GlassScriptPhysician profile
Anum Sikandar
NPI 1376104463
$842.47
in general payments reported to CMS, 2019-2025
10 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.93 · 2023: $214 · 2024: $453 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.24 | 2023-2024 | Lifevest |
| Recor Medical INC | $192.02 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $91.29 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.16 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $68.70 | 2023 | |
| Abbvie INC. | $58.80 | 2023-2024 | Dalvance |
| Melinta Therapeutics, LLC | $52.26 | 2024-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.93 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $19.71 | 2024 | Dificid, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $19.36 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anum Sikandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.